CASI Pharma (CASI) Tops Q2 EPS by 2c

CASI Pharma (NASDAQ: CASI) reported Q2 EPS of ($0.05), $0.02 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $7.16 million versus the consensus estimate of $6.02 million.

• Revenue Growth Guidance in 2021 Revised to Exceed 80% Over 2020

For earnings history and earnings-related data on CASI Pharma (CASI) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c
• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty